We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Moderna Inc 28 June 2024 EMA Committee For Medicinal Products For Human Use Adopts Positive Opinion Recommending Marketing Authorization Of Moderna's RSV Vaccine, mRESVIA(R) Moderna, Inc...
A row between pharmaceutical firms Moderna Inc and Pfizer Inc/BioNTech comes to court in London on Tuesday over paten ...
Moderna Inc 26 March 2024 Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine · mRNA-1283 induced a more robust immune response compared to...
Merck & Co Inc on Friday said its drug belzutifan was approved by the US Food & Drug Administration. The news follow ...
Moderna Inc Chief Executive Officer Stephane Bancel told AFP his company's experimental vaccine against melanoma coul ...
Merck & Co Inc on Friday and Monday updated investors on two developments regarding its cancer treatment, Keytruda. ...
Moderna Inc 07 December 2023 Moderna Reviews its Environmental, Social and Governance (ESG) Progress and Ambitions at Second ESG Investor Event The Company's ESG strategy demonstrates its...
Moderna Inc 30 October 2023 CEPI AND MODERNA HARNESS MRNA TECHNOLOGY TO ADVANCE 100 DAYS MISSION New partnership will harness Moderna's mRNA rapid-response platform, clinically validated...
The US on Monday approved Covid vaccines with formulations that more closely target currently circulating variants, a ...
Moderna Inc on Wednesday said it submitted a marketing authorisation application for the investigational respiratory ...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions